| Literature DB >> 26683668 |
Wonsik Lee1, Kaitlin Schaefer1,2, Yuan Qiao1,2, Veerasak Srisuknimit2, Heinrich Steinmetz3, Rolf Müller3, Daniel Kahne2, Suzanne Walker1.
Abstract
Lysobactin, also known as katanosin B, is a potent antibiotic with in vivo efficacy against Staphylococcus aureus and Streptococcus pneumoniae. It was previously shown to inhibit peptidoglycan (PG) biosynthesis, but its molecular mechanism of action has not been established. Using enzyme inhibition assays, we show that lysobactin forms 1:1 complexes with Lipid I, Lipid II, and Lipid II(A)(WTA), substrates in the PG and wall teichoic acid (WTA) biosynthetic pathways. Therefore, lysobactin, like ramoplanin and teixobactin, recognizes the reducing end of lipid-linked cell wall precursors. We show that despite its ability to bind precursors from different pathways, lysobactin's cellular mechanism of killing is due exclusively to Lipid II binding, which causes septal defects and catastrophic cell envelope damage.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26683668 PMCID: PMC4817722 DOI: 10.1021/jacs.5b11807
Source DB: PubMed Journal: J Am Chem Soc ISSN: 0002-7863 Impact factor: 15.419